Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Commercial availability
The Wegovy brand of semaglutide is not commercially available yet....
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Commercial arrangement
There is a simple discount patient access scheme for eptinezumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact United...
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Commercial arrangement
There is a simple discount patient access scheme for cannabidiol. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS orga...
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.
Commercial arrangement
There is a simple discount patient access scheme for polatuzumab vedotin. NHS organisations can get ...
Sandbrink, Friedhelm;
Murphy, Jennifer L;
Johansson, Melanie;
Olson, Juli L;
Edens, Ellen;
Clinton-Lont, Jamie;
Sall, James;
Spevak, Christopher;
Brown, Nicole;
Guinta, Raquel;
Macedo, Franz;
Nazario, Mitchell;
Pangarkar, Sanjog;
Preston, Samuel;
Prince, Matthew;
Real, Donna Endsley;
Riegleman, David;
Steil, Evan.
In May 2022, leadership within the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the use of opioids when managing chronic pain. This synopsis summarizes the recommendations that the authors believe are the most important to ...
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Commercial arrangement
There is a simple discount patient access scheme for vutrisiran. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NH...
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for regorafenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS or...
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Commercial arrangement
There is a commercial arrangement for nivolumab. NHS organisations can get...
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.
Commercial arrangement
There is a simple discount patient access scheme for upadacitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. N...
Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over....
